Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland

11. Literatur 218
270. Marugg RC, van der Mooren MJ, Hendriks JH, Rolland R, Ruijs S. Mammographic
changes in postmenopausal women on hormone replacement therapy. Eur Radiol
1997;7:749–55.
271. Maskarinec G, Meng L, Ursin G. Ethnic differences in mammographic densities. Int J
Epidemiol 2001;30:959–65.
272. Matthews BD, Williams GB. Initial experience with the advanced breast biopsy instrumentation
system. Am J Surg 1999;177:97–101.
273. McCredie M, Paul C, Skegg DC, Williams S. Reproductive factors and breast cancer in
New Zealand. Int J Cancer 1998;76:182–8.
274. McNicholas M, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP.
Pain and increased mammographic density in women receiving hormone replacement
therapy: a prospective study. Am J Roentgenol 1994;163:311–5.
275. medCERTAIN-Projekt. medCERTAIN-Projekt. 2002.
276. Meyer JE, Smith DN, Di Piro PJ, et al. Stereotactic breast biopsy of clustered
microcalcifications with a directional, vacuum-assisted device. Radiology 1997;204:
575–6.
277. Meyer JE, Smith DN, Lester SC, et al. Large core needle biopsy: nonmalignant breast
abnormalities evaluated with surgical excision or repeat core biopsy. Radiology
1998;206:717–9.
278. Miller B E. Breast cancer risk assessment in patients seen in a gynecolog-oncology
clinic. Int J Gynecol Cancer 2002;12:389–93.
279. Miller AB, To T, Baines CB, et al. The Canadian National Breast Screening Study:
update on breast cancer mortality. J Natl Cancer Inst Monogr 1997;22:37–41.
280. Miller J, Petrie J. Development of practice guidelines. The Lancet 2000;355:82–3.
281. Minckwitz von G, Brunnert K, Costa S, Friedrichs K, Gerber B, Harbeck N, et al.
Evidenzbasierte Empfehlung zur Primärbehandlung von Mammakarzinomen. Der
Konsensus der AGO-Organkommission „Mamma“. Zentralbl Gynäkol 2002;124:
293–303.
282. Minckwitz von G, Costa S, Brunnert K, Dall P, Nitz U, Diel I, et al. Evidenzbasierte
Empfehlung zur Behandlung von lokoregionär und fernmetastasierten Mammakarzinom.
Konsensus der AGO-Organkommission „Mamma“. Zentralbl Gynäkol
2002;124:282.
283. Morris J, et al. The use of quality of life data in clinical practice. Qual Life Res 1998;
7:85–91.
284. Mühlhäuser I, et al. Mammographic-Screening: Darstellung der wissenschaftlichen
Evidenz als Grundlage der Kommunikation mit der Frau. ZaeFQ 2000;94:721–31.
285. Müller-Schimpfle M OKCC. Einfluss von Alter und Menstruationszyklus auf Mammographie
und MR-Mammographie. Radiologe 1997;37:718–25.
286. Nass-Griegoleit I, et al. Brustkrebs-Früherkennung – Ältere Frauen verstärkt zur Teilnahme
an der Untersuchung motivieren. Frauenarzt 2002;43:257–60.
287. National Breast Cancer Centre R. Risk factors for breast cancer: a guide for general
practitioners, Australia. 1997.
288. National Cancer Institute. SEER Cancer Statistics Review 1973–1997. 2000.
289. National Cancer Institute. PDQ Prevention of breast cancer. 1999.
290. National Health and Medical Research Council (NHMRC). Clinical practice guideline
for the management of early breast cancer, second edition ed. Commonwealth of
Australia, 2001.
291. NHS Breast Screening Programme. Guidelines for Cytology Procedures and Reporting
in Breast Cancer Screening: Report by Cytology Sub-Group of the National
Coordinating Committee for Breast Screening Pathology. NHSBSP Publication
1993;22.